Therapy for Children With Neuroblastoma
Completed
This is a phase II window study of the combination of ZD1839 (gefitinib) and irinotecan in children with high-risk neuroblastoma followed by standard induction chemotherapy, intensification with autologous stem cell transplantation, and an oral maintenance phase with 13-cis-retinoic acid and topotecan. We hypothesize that the ZD1839 (gefitinib) and irinotecan window will be efficacious.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
06/02/2008
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma